Loading...
Market
GSK achieves €500 million revenue from mRNA vaccines by end of 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
GSK financial reports and earnings releases
Story
GSK Acquires Full Rights to Develop mRNA Flu and COVID-19 Vaccines from CureVac for €1.4 Billion
Jul 3, 2024, 07:27 AM
GSK and CureVac have restructured their collaboration into a new licensing agreement. As part of the deal, GSK will acquire full rights to develop and manufacture mRNA flu and COVID-19 shots from CureVac. The agreement includes a payment of up to €1.4 billion.
View original story
Similar markets
Under $1 billion • 33%
$1 billion - $2 billion • 33%
Over $2 billion • 33%
Positive • 33%
Neutral • 33%
Negative • 33%
Under $500 million • 33%
$500 million - $1 billion • 33%
Over $1 billion • 33%
Yes • 50%
No • 50%
Wave Life Sciences • 25%
ProQR Therapeutics • 25%
Korro Bio • 25%
Other • 25%
Less than €100 million • 33%
Between €100 million and €500 million • 33%
More than €500 million • 33%
Successful market introduction • 25%
Delayed market introduction • 25%
Project discontinued • 25%
Acquisition divested • 25%